Intermittent Low-Dose MDMA for Neuroergonomic Optimization: A Systems Framework for Minimum Effective Functional Dosing, Harm Reduction, and Autonomous Integration

Abstract

Research on 3,4-methylenedioxymethamphetamine (MDMA) has concentrated on moderate-to-high doses used in psychotherapy, controlled laboratory studies, and non-medical settings. This conceptual review asks whether intermittent, functionally perceptible low-dose exposure should be investigated as a distinct psychopharmacological architecture optimized for cumulative multi-day function rather than acute experiential intensity. It introduces the Minimum Effective Functional Dose (MEFD), defined as the lowest tested exposure that produces a prespecified functional improvement while remaining below prespecified physiological and post-acute burden thresholds. The framework evaluates a three-phase cycle comprising Modulation, Consolidation, and Post-Acute Functional Verification, with autonomous drug-free continuation as the decisive outcome. It further replaces a single benefit-to-burden ratio with a multidimensional Benefit-to-Burden Profile integrating task initiation, independently verified output, correction burden, sleep, cardiovascular and autonomic responses, mood stability, endocrine measures, and task-compatible neurophysiological endpoints. The model distinguishes established human evidence, mechanistically supported inference, and falsifiable conceptual hypotheses. It treats expectancy, functional unblinding, project-level carryover, cytochrome P450 2D6 (CYP2D6) autoinhibition, and possible cumulative 5-hydroxytryptamine receptor 2B (5-HT2B)-mediated valvular effects as design constraints. A seventy-two-hour cycle is proposed only as a provisional functional test architecture, not as evidence of complete metabolic recovery. Future research should proceed sequentially from single-dose range finding to three-day validation, interval comparison, bounded repeated-cycle studies, and longitudinal safety assessment. The article defines an experimentally testable program for determining whether a small transient intervention can generate durable drug-free work with less biological cost than stronger or continuous pharmacological architectures.